Cipla Ltd - 500087 - USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., received one inspectional observation in Form 483 from the USFDA. This followed a routine cGMP inspection of its Central Islip, NY manufacturing facility from July 13-17, 2026. The company committed to addressing the observation.
Jul 18 2026 09:33:48
Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla received ESG ratings 'Crisil ESG 69' and 'Crisil Core ESG 66' from Crisil ESG Ratings & Analytics Limited on its environmental, social, and governance performance. This independent assessment provides transparency on the company's sustainability practices.
Jul 12 2026 11:26:46
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Cipla will host an earnings conference call on July 23, 2026, to discuss its Q1 FY27 unaudited financial results. The leadership team will address financial performance and take questions from investors and analysts.
Jul 08 2026 13:33:48
Cipla Ltd - 500087 - Transcript Of The 90Th Annual General Meeting
Cipla held its 90th Annual General Meeting, where shareholders approved the FY26 financial results, which included record revenue exceeding Rs.28,000 crores. A final dividend of Rs.30 per share was declared, and BSR & Co. LLP was appointed as the new statutory auditor for a five-year term. The company also highlighted positive USFDA compliance status for its facilities.
Jul 03 2026 18:31:02
Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla's ESG rating was downgraded to 64 from 68 by ESGRisks.ai, a SEBI registered rating provider. The revision is based on re-evaluation of publicly available information and new data from the assessment period.
Jun 25 2026 15:02:13
Cipla Ltd - 500087 - Board Meeting Intimation for The Quarter Ended 30Th June, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla's Board of Directors is scheduled to meet on Thursday, July 23, 2026. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This intimation provides advance notice of the upcoming financial disclosure.
Jun 24 2026 17:56:18
Read More